Biodistribution of free and N-(2-hydroxypropyl)methacrylamide copolymer-bound mesochlorin e6 and adriamycin in nude mice bearing human ovarian carcinoma OVCAR-3 xenografts

Journal of Controlled Release

Volumn 61, Issue 1-2, 1999, Pages 145-157

  Shiah, Jane Guo ^a   Sun, Yongen ^c   Peterson, C Matthew ^b   Kopeček, Jindřich ^a  

^a Dept Pharmaceut Pharmaceutical C ^*  (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Adriamycin (doxorubicin); Biodistribution; EPR effect; Mesochlorin e6 monoethylenediamine; N (2 Hydroxypropyl)methacrylamide copolymer

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; ETHYLENEDIAMINE; N (2 HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG DISTRIBUTION; DRUG PENETRATION; FEMALE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; DOXORUBICIN; FEMALE; HUMANS; METHACRYLATES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032854773     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(99)00113-3     Document Type: Article

References (42)

1. Levy J.G. Photodynamic therapy. Trends Biotechnol. 13:1995;14-18.
2. Kessel D., Woodburn K., Henderson B.W., Chang C.K. Sites of photodamage in vivo and in vitro by a cationic porphyrin. Photochem. Photobiol. 62:1995;875-881.
3. Ochsner M. Photodynamic therapy: the clinical perspective. Drug Res. 47:1997;1185-1194.
4. Henderson B.W., Dougherty T.J. Photodynamic Therapy: Basic Principles and Clinical Applications. 1992;Marcel Dekker, New York.
5. Kessel D., Woodburn K. Biodistribution of photosensitizing agents. Int. J. Biochem. 25:1993;1377-1383.
6. Levy J.G. Photosensitizers in photodynamic therapy. Semin. Oncol. 21:1994;4-10.
7. Chabner B.A., Longo D.L. Cancer Chemotherapy and Biotherapy: Principles and Practice. second ed :1996;Lippincott-Raven, Philadelphia, New York.
8. Mihich E. Immunity and cancer therapy: present status and future projections. Goldfarb R.H., Whiteside T.L. Tumor Immunology and Cancer Therapy. 1994;Marcel Dekker, New York.
9. Putnam D., Kopeček J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
10. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anticancer Drugs. 3:1992;175-210.
11. Takakura Y., Hashida M. Macromolecular carrier systems for targeted drug delivery: pharmacokinetic considerations on biodistribution. Pharm. Res. 13:1996;820-831.
12. Howell S.B., Kirmani S., McClay E.F., Kim S., Braly P., Plaxe S. Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma. Semin. Oncol. 18:1991;5-10.
13. Molpus K.L., Kato D., Hamblin M.R., Lilge L., Bamberg M., Hasan T. Intraperitoneal photodynamic therapy of human epithelial ovarian carcinomatosis in a xenograft murine model. Cancer Res. 56:1996;1075-1082.
14. Datta S.N., Allman R., Loh C., Mason M., Matthews P.N. Effect of photodynamic therapy in combination with mitomycin C on a mitomycin-resistant bladder cancer cell line. Br. J. Cancer. 76:1997;312-317.
15. Ma L.W., Moan J., Steen H.B., Iani V. Anti-tumor activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma. Br. J. Cancer. 71:1995;950-956.
16. Brophy P.F., Keller S.M. Adriamycin enhanced in vitro and in vivo photodynamic therapy of mesothelioma. J. Surg. Res. 52:1992;631-634.
17. Baas P., van Geel I.P.J., Oppelaar H., Meyer M., Beynen J.H., van Zandwijk N., Stewart F.A. Enhancement of photodynamic therapy by mitomycin C: a preclinical and clinical study. Br. J. Cancer. 73:1996;945-951.
18. 6 monoethylene diamine in human epithelial ovarian carcinoma (OVCAR-3) in vitro. J. Soc. Gynecol. Invest. 2:1995;772-777.
19. Rejmanová P., Pohl J., Baudyš M., Kostka V., Kopeček J. Polymers containing enzymatically degradable bonds. 8. Degradation of oligopeptide sequences in N-(2-hydroxypropyl)methacrylamide copolymers by bovine spleen cathepsin B. Makromol. Chem. 184:1983;2009-2020.
20. Vasey P.A., Kaye S.B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A.H., Murray L.S., Hilditch T.E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: First member of a new class of chemotherapeutic agents - drug-polymer conjugates. Clin. Cancer Res. 5:1999;83-94.
21. Krinick N.L., Sun Y., Joyner D., Spikes J.D., Straight R.C., Kopeček J. A polymeric drug delivery system for the simultaneous delivery of drugs activatable by enzymes and/or light. J. Biomater. Sci. Polym. Ed. 5:1994;303-324.
22. Peterson C.M., Lu J.M., Sun Y., Peterson C.A., Shiah J.-G., Straight R.C., Kopeček J. Combination chemotherapy and photodynamic therapy with N-(2-hydroxypropyl)methacrylamide copolymer-bound anticancer drugs inhibit human ovarian carcinoma heterotransplanted in nude mice. Cancer Res. 56:1996;3980-3985.
23. 6 and adriamycin conjugates in combination treatments, submitted.
24. Cummings J., Stuard J.F.B., Calman K.C. Determination of adriamycin, adriamycinol and their 7-deoxyaglycones in human serum by high performance liquid chromatography. J. Chromatogr. 311:1984;125-133.
25. 6 in the mouse. Photochem. Photobiol. 56:1992;51-56.
26. 125I daunomycin. J. Control. Release. 10:1989;37-49.
27. Seymour L.W., Ulbrich K., Strohalm J., Kopeček J., Duncan R. The pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39:1990;1125-1131.
28. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma. J. Drug Target. 3:1996;385-390.
29. 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma. J. Drug Target. 3:1996;375-383.
30. Seymour L.W., Ulbrich K., Steyger P.S., Brereton M., Subr V., Strohalm J., Duncan R. Tumor tropism and anti-cancer efficacy of polymer-based doxorubicin prodrugs in the treatment of subcutaneous murine B16F10 melanoma. Br. J. Cancer. 70:1994;636-641.
31. Cassidy J., Duncan R., Morrison G.J., Strohalm J., Plocová D., Kopeček J., Kaye S.B. Activity of N-(2-hydroxypropyl)methacrylamide copolymers containing daunomycin against a rat tumor model. Biochem. Pharmacol. 38:1989;875-879.
32. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Microcirculation. 4:1997;1-23.
33. Baxter L.T., Jain R.K. Transport of fluid and macromolecules in tumors: II. Role of heterogeneous perfusion and lymphatics. Microvasc. Res. 40:1990;246-252.
34. Baish J.W., Gazit Y., Berk D.A., Nozue M., Baxter L.T., Jain R.K. Role of tumor vascular architecture in nutrient and drug delivery: an invasion percolation-based network model. Microvasc. Res. 51:1996;327-346.
35. Dvorak H.F., Nagy J.A., Dvorak A.M. Structure of solid tumors and their vasculature: implication for therapy with monoclonal antibodies. Cancer Cells. 3:1991;77-83.
36. Yeo K.T., Wang H.H., Nagy J.A., Dvorak A.M. Vascular permeability factor (vascular endothelial growth factor) in guinea pig and human tumor and inflammatory effusions. Cancer Res. 53:1993;2912-2919.
37. Feng D., Nagy J.A., Hipp J., Dvorak H.F., Dvorak A.M. Vesiculo-vacuolar organelles and the regulation of venule permeability to macromolecules by vascular permeability factor, histamine, and serotonin. J. Exp. Med. 183:1996;1981-1986.
38. Baish J.W., Netti P.A., Jain R.K. Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc. Res. 53:1997;128-141.
39. Maeda H., Seymour L.W., Miyamoto Y. Conjugates of anticancer agents and polymers: advantages of macromolecular therapeutics in vivo. Bioconjugate Chem. 3:1992;351-355.
40. Yeung T.K., Hopewell J.W., Simmonds R.H., Seymour L.W., Duncan R., Bellini O., Grandi M., Spreafico F., Strohalm J., Ulbrich K. Reduced cardiotoxicity of doxorubicin given in the form of N-(2-hydroxypropyl)methacrylamide conjugates: an experimental study in the rat. Cancer Chemother. Pharmacol. 29:1991;105-111.
41. Rypáček F., Drobník J., Chmelař V., Kálal J. The renal excretion and retention of macromolecules. The chemical structure effect. Pflug. Arch. Eur. J. Physiol. 392:1982;211-217.
42. 6 conjugates. Drug Deliv. 5:1998;119-126.